LANCET:新发现:脑膜炎疫苗竟然是性传播疾病的强大克星!

2017-07-11 枫丹白露 来宝网

研究人员星期二说,针对导致脑部炎症的细菌的一种停用疫苗也保护了人们免受淋病,这是迄今为止首例提供这种防止性传播疾病的药物。



离淋病疫苗又进了一步?】研究人员星期二说,针对导致脑部炎症的细菌的一种停用疫苗也保护了人们免受淋病,这是迄今为止首例提供这种防止性传播疾病的药物。

根据世界卫生组织(WHO)的数据,使用避孕套或戒除性生活现在是避免每年感染约8000万人的淋病感染的唯一方法。

随着耐药性的扩大,医生正在诊断越来越多的不能被抗生素治疗的病例,这成为一个重大的公共卫生问题。

就在上周,世卫组织表示迫切需要新药来预防和治疗淋病,这是通过阴道,口腔和肛交传播的。未经治疗,可引起女性疼痛性盆腔炎,男性不孕。在极端情况下,细菌可以在血液中扩散,从而在身体的其他部位引起危及生命的感染。

如果孕妇感染,淋病可能导致她未出生的孩子失明。

这种疾病很容易传播,因为许多携带者不知道他们的感染,也不知不觉地将其传递给新的性伴侣。

对于在“柳叶刀”中发表的新研究,研究人员在2004年至2006年间向超过一百万新西兰人施用的脑膜炎球菌B疫苗的患者中查看了诊断出淋病的病例。

通过咳嗽或接吻传播的脑膜炎球菌可引起脑膜炎,脑和脊髓的炎症,以及称为败血症的血液感染。两者都可能是致命的。

研究人员说,虽然症状和传播方式差异很大,但脑膜炎和淋病是非常接近的基因匹配。

专家最近注意到脑膜炎球菌B疫苗运动后淋病的下降。

所以团队开始进行调查,发现在新西兰获得脑膜炎疫苗的人“比没有得到接种的人明显不太可能患有淋病”。

估计疫苗的淋病减少了31%,这个水平将使15年内疾病流行率下降约三分之一。

新西兰奥克兰大学的Helen Petousis-Harris研究合着者Helen Petousis-Harris说:“这是疫苗第一次显示防止淋病的保护作用。

免疫系统如何触发淋病是不明白的,疫苗在特定疫情中使用不再可用。

然而,使用一些相同的分子来制造仍在使用的另一种脑膜炎球菌疫苗。

澳大利亚格里菲斯大学糖尿病研究所的Kate Seib在研究报告中写道:进一步的研究对于确定脑膜炎疫苗如何阻止淋病是至关重要的。

“鉴于疾病的高负担和由于抗生素耐药而使淋病的威胁变得无法治愈,因此越来越需要重新审视疫苗选择并重新开展这一领域的研究。”

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829077, encodeId=2fcc18290e729, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 02 06:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921180, encodeId=a97b192118004, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Mar 05 04:07:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981547, encodeId=0722198154ead, content=<a href='/topic/show?id=1f6d8506136' target=_blank style='color:#2F92EE;'>#脑膜炎疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85061, encryptionId=1f6d8506136, topicName=脑膜炎疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed May 02 16:07:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419197, encodeId=bcec141919e5f, content=<a href='/topic/show?id=3c605261e16' target=_blank style='color:#2F92EE;'>#性传播#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52617, encryptionId=3c605261e16, topicName=性传播)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1853475132, createdName=hywen7327, createdTime=Thu Jul 13 09:07:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221385, encodeId=293322138531, content=学习过了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Jul 12 11:03:17 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221171, encodeId=379d2211e1c7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Tue Jul 11 22:51:49 CST 2017, time=2017-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221154, encodeId=72cf22115416, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Jul 11 22:29:56 CST 2017, time=2017-07-11, status=1, ipAttribution=)]
    2018-06-02 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829077, encodeId=2fcc18290e729, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 02 06:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921180, encodeId=a97b192118004, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Mar 05 04:07:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981547, encodeId=0722198154ead, content=<a href='/topic/show?id=1f6d8506136' target=_blank style='color:#2F92EE;'>#脑膜炎疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85061, encryptionId=1f6d8506136, topicName=脑膜炎疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed May 02 16:07:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419197, encodeId=bcec141919e5f, content=<a href='/topic/show?id=3c605261e16' target=_blank style='color:#2F92EE;'>#性传播#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52617, encryptionId=3c605261e16, topicName=性传播)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1853475132, createdName=hywen7327, createdTime=Thu Jul 13 09:07:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221385, encodeId=293322138531, content=学习过了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Jul 12 11:03:17 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221171, encodeId=379d2211e1c7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Tue Jul 11 22:51:49 CST 2017, time=2017-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221154, encodeId=72cf22115416, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Jul 11 22:29:56 CST 2017, time=2017-07-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1829077, encodeId=2fcc18290e729, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 02 06:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921180, encodeId=a97b192118004, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Mar 05 04:07:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981547, encodeId=0722198154ead, content=<a href='/topic/show?id=1f6d8506136' target=_blank style='color:#2F92EE;'>#脑膜炎疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85061, encryptionId=1f6d8506136, topicName=脑膜炎疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed May 02 16:07:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419197, encodeId=bcec141919e5f, content=<a href='/topic/show?id=3c605261e16' target=_blank style='color:#2F92EE;'>#性传播#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52617, encryptionId=3c605261e16, topicName=性传播)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1853475132, createdName=hywen7327, createdTime=Thu Jul 13 09:07:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221385, encodeId=293322138531, content=学习过了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Jul 12 11:03:17 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221171, encodeId=379d2211e1c7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Tue Jul 11 22:51:49 CST 2017, time=2017-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221154, encodeId=72cf22115416, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Jul 11 22:29:56 CST 2017, time=2017-07-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1829077, encodeId=2fcc18290e729, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 02 06:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921180, encodeId=a97b192118004, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Mar 05 04:07:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981547, encodeId=0722198154ead, content=<a href='/topic/show?id=1f6d8506136' target=_blank style='color:#2F92EE;'>#脑膜炎疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85061, encryptionId=1f6d8506136, topicName=脑膜炎疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed May 02 16:07:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419197, encodeId=bcec141919e5f, content=<a href='/topic/show?id=3c605261e16' target=_blank style='color:#2F92EE;'>#性传播#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52617, encryptionId=3c605261e16, topicName=性传播)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1853475132, createdName=hywen7327, createdTime=Thu Jul 13 09:07:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221385, encodeId=293322138531, content=学习过了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Jul 12 11:03:17 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221171, encodeId=379d2211e1c7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Tue Jul 11 22:51:49 CST 2017, time=2017-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221154, encodeId=72cf22115416, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Jul 11 22:29:56 CST 2017, time=2017-07-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1829077, encodeId=2fcc18290e729, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 02 06:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921180, encodeId=a97b192118004, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Mar 05 04:07:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981547, encodeId=0722198154ead, content=<a href='/topic/show?id=1f6d8506136' target=_blank style='color:#2F92EE;'>#脑膜炎疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85061, encryptionId=1f6d8506136, topicName=脑膜炎疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed May 02 16:07:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419197, encodeId=bcec141919e5f, content=<a href='/topic/show?id=3c605261e16' target=_blank style='color:#2F92EE;'>#性传播#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52617, encryptionId=3c605261e16, topicName=性传播)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1853475132, createdName=hywen7327, createdTime=Thu Jul 13 09:07:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221385, encodeId=293322138531, content=学习过了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Jul 12 11:03:17 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221171, encodeId=379d2211e1c7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Tue Jul 11 22:51:49 CST 2017, time=2017-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221154, encodeId=72cf22115416, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Jul 11 22:29:56 CST 2017, time=2017-07-11, status=1, ipAttribution=)]
    2017-07-12 明天会更好!

    学习过了,谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1829077, encodeId=2fcc18290e729, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 02 06:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921180, encodeId=a97b192118004, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Mar 05 04:07:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981547, encodeId=0722198154ead, content=<a href='/topic/show?id=1f6d8506136' target=_blank style='color:#2F92EE;'>#脑膜炎疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85061, encryptionId=1f6d8506136, topicName=脑膜炎疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed May 02 16:07:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419197, encodeId=bcec141919e5f, content=<a href='/topic/show?id=3c605261e16' target=_blank style='color:#2F92EE;'>#性传播#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52617, encryptionId=3c605261e16, topicName=性传播)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1853475132, createdName=hywen7327, createdTime=Thu Jul 13 09:07:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221385, encodeId=293322138531, content=学习过了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Jul 12 11:03:17 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221171, encodeId=379d2211e1c7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Tue Jul 11 22:51:49 CST 2017, time=2017-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221154, encodeId=72cf22115416, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Jul 11 22:29:56 CST 2017, time=2017-07-11, status=1, ipAttribution=)]
    2017-07-11 维维豆奶

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1829077, encodeId=2fcc18290e729, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jun 02 06:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921180, encodeId=a97b192118004, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Mar 05 04:07:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981547, encodeId=0722198154ead, content=<a href='/topic/show?id=1f6d8506136' target=_blank style='color:#2F92EE;'>#脑膜炎疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85061, encryptionId=1f6d8506136, topicName=脑膜炎疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed May 02 16:07:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419197, encodeId=bcec141919e5f, content=<a href='/topic/show?id=3c605261e16' target=_blank style='color:#2F92EE;'>#性传播#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52617, encryptionId=3c605261e16, topicName=性传播)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1853475132, createdName=hywen7327, createdTime=Thu Jul 13 09:07:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221385, encodeId=293322138531, content=学习过了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Jul 12 11:03:17 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221171, encodeId=379d2211e1c7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Tue Jul 11 22:51:49 CST 2017, time=2017-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221154, encodeId=72cf22115416, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Jul 11 22:29:56 CST 2017, time=2017-07-11, status=1, ipAttribution=)]
    2017-07-11 清风拂面

    学习了,谢谢分享

    0

相关资讯

霍乱疫苗在也门面临大规模测试

试想在一个面积和西班牙相当、饱受战争蹂躏的贫困国家,有2000余万人受到一种在城市间快速传播的致命疾病的威胁。你可以支配100万份疫苗。你会试图保护谁?

Nature:个性化癌症疫苗在早期人体试验中表现乐观

本周《自然》在线发表的两篇论文An immunogenic personal neoantigen vaccine for patients with melanoma和Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer中,展示了两种个性化的癌症疫苗的接种在小规模

肺炎13价疫苗登陆上海,超6个月宝宝不能接种

备受年轻家长青睐的13价肺炎疫苗现已登陆上海。13价肺炎疫苗仅针对6周龄至15月龄宝宝,2周岁以上的宝宝可以选择接种23价肺炎疫苗。需要提醒的是,在大陆地区,宝宝超过6月龄就不能接种13价肺炎疫苗。在所有疫苗可预防疾病中,肺炎球菌疾病是导致全球5岁以下儿童死亡的重要病因之一。初生至2岁间的儿童因缺乏相应抗体,是感染肺炎球菌性疾病的高危群体,而且更易得侵袭性肺炎球菌性疾病。肺炎13价疫苗可以预防由1

Lancet infect dis:在孟加拉国停用口服三价脊髓灰质病毒疫苗后脊髓灰质炎的传播情况。

2016年4月起,在全球范围内,三价口服脊髓灰质炎疫苗(tOPV)被二价I型和3型口服脊髓灰质炎疫苗(bOPV)和一剂量的灭活脊髓灰质炎病毒(IPV)所取代。对于这一改变后II型脊髓灰质炎病毒或Sabin2病毒(脊髓灰质炎病毒的一种)对于II型脊髓灰质炎的再次引入或发生的传播风险尚未完全清楚。

npj Vaccines:基于DNA新的策略,对流感病毒的治疗显示出希望

Wistar研究所MedImmune和Inovio Pharmaceuticals公司的科学家在临床前模型中开发了一种新颖、合成的基于DNA的策略,来提供针对各种流感病毒的保护。这些研究结果强调了这一有前景的策略,发表在npj疫苗上。

Nature:个性化新抗原疫苗引发强烈抗肿瘤反应,攻克癌症治疗两大障碍!

Dana-Farber癌症研究所和麻省理工学院广泛研究所的研究已经显示靶向肿瘤细胞上特征性的“新抗原”的个体癌症治疗疫苗可刺激黑素瘤患者的有效,安全和高度特异性的免疫抗肿瘤反应。